In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), with a price target of $60.00.
Mark Massaro has given his Buy rating due to a combination of factors including Guardant Health’s recent achievement of obtaining ADLT status for its Shield CRC test. This status, effective April 1, 2025, significantly increases the Medicare reimbursement rate for the test, marking a pivotal moment for both the company and the diagnostics industry. The ADLT status not only enhances the test’s value but also positions Guardant Health as a leader in pioneering industry advancements, having previously set benchmarks with its Guardant 360 test.
Furthermore, the anticipated revenue growth for Shield, driven by higher average selling prices, presents a promising financial outlook. The potential inclusion of Shield in the American Cancer Society guidelines could further expand its market reach, particularly in states with mandated commercial payor coverage. These developments, along with other upcoming catalysts such as data releases and rising ASPs, underpin Massaro’s confidence in the stock’s potential, justifying the Buy rating and a price target of $60.
In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 140 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.